Jennifer M Willen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Treatment for Angelman syndrome (AS) is currently limited to symptomatic interventions. A mouse model of AS has reduced calcium/calmodulin-dependent kinase II activity due to excessive phosphorylation of specific threonine residues, leading to diminished long-term potentiation. In a rat model of Parkinson disease, levodopa reduced phosphorylation of various(More)
  • 1